Platelets Rich PlasmaNCT07901920
Platelets Rich Plasma Injection Versus Physiologic Saline Injection for Treatment of Myofascial Pain
A study testing Platelet-rich plasma and Physiologic saline in people with Platelets Rich Plasma and Saline, run by Cairo University at 1 site in Egypt.
Trial summary
The aim of this is to compare the usage of Platelet-Rich Plasma (PRP) and Physiologic Saline injection in management of myofascial pain dysfunction (MPD). Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Platelets Rich Plasma, Saline, Myofascial Pain
- What is being tested?
- Platelet-rich plasma and Physiologic saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2026to 1 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female with age ranging from 20-40 years.
- Suffering from unilateral or bilateral signs and symptoms of myofascial pain dysfunction (MPD), selected patients were systemically free with no chronic diseases.
Who cannot join
- Patients with history of Malignancy or a history of previous surgery of neck and/or shoulder within the past year of the study.
- Any patient had treatment that can affect the muscles will be excluded, either pharmacological treatment (e.g., opioids, morphine, muscle relaxants or anti-depressants), physiotherapy management or occlusal appliances.
- Patients with pain of dental etiology.
- Pregnant and lactating women and patients with history of allergy or coagulation disorders.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Cairo, 11553
Abdul-Rahman A Salem, B.Sc, 00201000009344, a.aaskhalil@gmail.com
Hani H Amin, MD
About this study
Official title: Platelets Rich Plasma Injection Versus Physiologic Saline Injection for Treatment of Myofascial Pain: A Randomized Clinical Trial
The aim of this is to compare the usage of Platelet-Rich Plasma (PRP) and Physiologic Saline injection in management of myofascial pain dysfunction (MPD).
Read the detailed description
Myofascial Pain Syndrome (MPS) is a chronic pain disorder characterized by the presence of myofascial trigger points (TrPs), which are hypersensitive areas within the muscle or its surrounding fascia. These trigger points are typically associated with tight bands of muscle fibers and can cause localized and referred pain when compressed or stimulated.
MPS can affect any age group and is a significant cause of musculoskeletal pain, disability, and reduced quality of life. Its prevalence varies, with estimates suggesting it may impact up to 85% of individuals with chronic pain conditions. Despite its widespread occurrence, MPS often goes unrecognized due to its overlap with other pain disorders, such as fibromyalgia, tension headaches, or nerve-related conditions.
- Conditions
- Platelets Rich Plasma, Saline, Myofascial Pain
- Being tested
- Platelet-rich plasma, Physiologic saline
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Platelet-rich plasmaDrug
Patients will be treated with platelet-rich plasma (PRP) injection.
Physiologic salineDrug
Patients will be managed with physiologic saline injection.
| Study group | Role | What they receive |
|---|---|---|
| Group I | Experimental | Patients will be treated with platelet-rich plasma (PRP) injection. Receives: Drug: Platelet-rich plasma |
| Group II | Active comparator | Patients will be managed with physiologic saline injection. Receives: Drug: Physiologic saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Degree of pain
Pain level will be evaluated by using of Visual Analog Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable")
Measured: 24 weeks postoperatively
Secondary outcomes (7)
Mean maximum unassisted mouth opening (MUMO)
Maximum distance between the incisal edges of the upper and lower central incisors during mouth opening will be measured in millimeters.
Higher values indicate greater mouth opening.
Measured: 24 weeks postoperatively
Mean maximum assisted mouth opening (MAMO)
Maximum distance between the incisal edges of the upper and lower central incisors during mouth opening will be measured in millimeters.
Higher values indicate greater mouth opening.
Measured: 24 weeks postoperatively
Range of right lateral excursive movements
Maximum voluntary lateral movement of the mandible to the right will be measured in millimeters as the displacement of the lower dental midline relative to the upper dental midline from the starting position. Higher values indicate greater lateral mandibular mobility.
Measured: 24 weeks postoperatively
Range of left lateral excursive movements
Maximum voluntary lateral movement of the mandible to left will be measured in millimeters as the displacement of the lower dental midline relative to the upper dental midline from the starting position. Higher values indicate greater lateral mandibular mobility.
Measured: 24 weeks postoperatively
Range of protrusive movement
Maximum voluntary forward movement of the mandible from the starting bite position will be measured in millimeters and accounting for the initial horizontal relationship between the upper and lower incisors (overjet). Higher values indicate greater protrusive mandibular mobility.
Measured: 24 weeks postoperatively
Degree of patient satisfaction
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
Measured: 24 weeks postoperatively
Range of mandibular motion
Range of mandibular motion will be assessed quantitatively with the help of digital vernier calipers (in millimeters).
Measured: 24 weeks postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start1 May 2026
- Primary completion1 May 2027 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Platelets Rich PlasmaStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 28 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdul-Rahman Salem, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07901920
- Sponsor's protocol ID
- 4/2026
- Status last verified
- Oct 2026
- First submitted
- 22 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Platelets Rich Plasma Injection Versus Physiologic Saline Injection for Treatment of Myofascial Pain: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07901920
- Acronym / sponsor ID
- 4/2026
- Conditions
- Platelets Rich Plasma, Saline, Myofascial Pain
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 28 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (actual)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this is to compare the usage of Platelet-Rich Plasma (PRP) and Physiologic Saline injection in management of myofascial pain dysfunction (MPD).
Detailed description
Myofascial Pain Syndrome (MPS) is a chronic pain disorder characterized by the presence of myofascial trigger points (TrPs), which are hypersensitive areas within the muscle or its surrounding fascia. These trigger points are typically associated with tight bands of muscle fibers and can cause localized and referred pain when compressed or stimulated.
MPS can affect any age group and is a significant cause of musculoskeletal pain, disability, and reduced quality of life. Its prevalence varies, with estimates suggesting it may impact up to 85% of individuals with chronic pain conditions. Despite its widespread occurrence, MPS often goes unrecognized due to its overlap with other pain disorders, such as fibromyalgia, tension headaches, or nerve-related conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I | Experimental | Drug: Platelet-rich plasmaPatients will be treated with platelet-rich plasma (PRP) injection. |
| Group II | Active comparator | Drug: Physiologic salinePatients will be managed with physiologic saline injection. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Female with age ranging from 20-40 years.
- Suffering from unilateral or bilateral signs and symptoms of myofascial pain dysfunction (MPD), selected patients were systemically free with no chronic diseases.
Key exclusion criteria (4 listed)
- Patients with history of Malignancy or a history of previous surgery of neck and/or shoulder within the past year of the study.
- Any patient had treatment that can affect the muscles will be excluded, either pharmacological treatment (e.g., opioids, morphine, muscle relaxants or anti-depressants), physiotherapy management or occlusal appliances.
- Patients with pain of dental etiology.
- Pregnant and lactating women and patients with history of allergy or coagulation disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Platelet-rich plasmaPatients will be treated with platelet-rich plasma (PRP) injection. | Drug | Group I |
| Physiologic salinePatients will be managed with physiologic saline injection. | Drug | Group II |
Primary outcome
Degree of pain
Time frame: 24 weeks postoperatively
Pain level will be evaluated by using of Visual Analog Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable")
7 secondary outcomes
Mean maximum unassisted mouth opening (MUMO)
Time frame: 24 weeks postoperatively
Mean maximum assisted mouth opening (MAMO)
Time frame: 24 weeks postoperatively
Range of right lateral excursive movements
Time frame: 24 weeks postoperatively
Range of left lateral excursive movements
Time frame: 24 weeks postoperatively
Range of protrusive movement
Time frame: 24 weeks postoperatively
Degree of patient satisfaction
Time frame: 24 weeks postoperatively
Range of mandibular motion
Time frame: 24 weeks postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Platelets Rich Plasma
Not yet recruiting
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Not yet recruiting
Platelet-Rich Plasma, Hyaluronic Acid, or Their Combination for Knee Osteoarthritis in Athletes
Knee Osteoarthritis
Active, not recruitingPhase 4
Efficacy and Safety of Triple-Combination Cream Plus Microneedling Along With Tranexamic Acid Versus Platelet-Rich Plasma in the Treatment of Moderate-to-Severe Melasma: A Randomized Comparative Study
Melasma (Facial Melasma)
Active, not recruiting
Lyophilized Platelet-Rich Plasma Lysate vs Dextrose Prolotherapy for Partial Rotator Cuff Tears
Rotator Cuff Tear, Rotator Cuff Syndrome
RecruitingPhase 4
PRP for Glenohumeral Osteoarthritis
Shoulder Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Platelet-rich plasma and Physiologic saline in people with Platelets Rich Plasma and Saline, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Abdul-Rahman A Salem, B.Sc (00201000009344, a.aaskhalil@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Degree of pain (time frame: 24 weeks postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.